EP3970718A1 — New medical use of cystic fibrosis transmembrane conductance regulator (cftr) modulators
Assigned to Charite Universitaetsmedizin Berlin · Expires 2022-03-23 · 4y expired
What this patent protects
The invention relates to a cystic fibrosis transmembrane conductance regulator (CFTR) modulator for use in the prevention and/or treatment of diseases involving endothelial and/or epithelial barrier dysfunctions.The invention further relates to a pharmaceutical composition compri…
USPTO Abstract
The invention relates to a cystic fibrosis transmembrane conductance regulator (CFTR) modulator for use in the prevention and/or treatment of diseases involving endothelial and/or epithelial barrier dysfunctions.The invention further relates to a pharmaceutical composition comprising a CFTR modulator as an active ingredient for use in the prevention and/or treatment of diseases involving endothelial and/or epithelial barrier dysfunctions.The invention further relates to a kit of parts for use in the prevention and/or treatment of diseases involving endothelial and/or epithelial barrier dysfunctions comprising i) a CFTR modulator and ii) a further CFTR modulator.The invention further relates to a method of treating a condition, disease or disorder involving endothelial and/or epithelial barrier dysfunctions in a subject, the method comprising administering a CFTR modulator to a subject, preferably a mammal, in the need thereof.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.